Market Overview:
The global opioid use disorder market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The growth in this market can be attributed to factors such as the increasing prevalence of opioid use disorders, rising demand for opioids for moderate and severe pain treatment, and growing awareness about available treatment options. The global opioid use disorder market is segmented on the basis of type into buprenorphine, methadone, and naltrexone. The buprenorphine segment is expected to account for the largest share of the global opioid use disorder market in 2018. This segment is projected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. This growth can be attributed to factors such as its high efficacy in treating opioid addiction and its wide availability through prescription drug programs and clinics across major countries worldwide. On the basis of application,the global opioid use disorder market is divided into moderate pain treatment and severe pain treatment segments.
Product Definition:
Opioid use disorder is a condition that results when someone uses opioids in a manner that causes problems. These problems can include development of tolerance to the drug, so that more and more is needed to achieve the desired effect (tolerance), dependence on opioids, meaning that withdrawal symptoms will occur if use is stopped suddenly (dependence), and addiction, which refers to compulsive drug-taking despite negative consequences.
Buprenorphine:
Buprenorphine is a partial opioid agonist, which means it binds to the same receptors as full opioid agonists but has lower potency. Buprenorphine is used in the treatment of severe chronic pain and as an analgesic (pain reducer) in people who are experiencing physical dependency on opioids. Opioid Use Disorder (OUD) includes both OUD-1 and OUD-2 conditions.
Methadone:
Methadone is a synthetic opiate that was first developed as an anti-addiction drug in 1960. It has been used to treat opioid addiction since then and currently, it is one of the most commonly prescribed drugs for detoxification and maintenance therapy in the U.S. According to data published by CDC, methadone use disorder treatment was responsible for around 11% of all opioid treatments administered during 2014-2016 period which accounts approximately 4 million patients across 50 states in U.
Application Insights:
The moderate pain treatment segment dominated the global market in 2017, owing to the growing incidence of chronic diseases such as arthritis and cancer, which are associated with intense pain. According to WHO, it is estimated that around 1 in 5 people aged 60 years and above have some form of arthritis. Similarly, WHO has reported that about 2-3% of the total population of the world will develop cancer during their lifetime. These factors indicate a significant growth potential for opioid analgesic drugs in near future.
However, severe pain treatment is expected to be one of the fastest-growing segments over forecast period due largely to increasing number of drug abuse cases across various regions including North America and Europe & Central & South America.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of a large number of opioid-tolerant patients, high per capita income, and favorable government initiatives. The region is expected to maintain its dominance throughout the forecast period due to increasing awareness about OUD treatment options and growing demand for pain management therapies.
Asia Pacific is anticipated to be one of the fastest-growing regions over the forecast period owing to rising disposable income levels, improving healthcare infrastructure facilities in economies including China & India, and increasing patient awareness about OUD treatment options. Moreover, governments are introducing various policies that aim at reducing drug abuse by providing alternative medication choices such as buprenorphine/naloxone combination products for treating opioid use disorder (OUD).
Growth Factors:
- Increasing awareness about the risks associated with opioid use and addiction.
- Growing number of prescription opioids available for sale.
- More people addicted to prescription opioids turning to heroin as a cheaper alternative.
- Increased availability of naloxone, which can reverse the effects of an opioid overdose.
- Expansion of medication-assisted treatment programs for opioid addiction
Scope Of The Report
Report Attributes
Report Details
Report Title
Opioid Use Disorder Market Research Report
By Type
Buprenorphine, Methadone, Naltrexone
By Application
Moderate Pain Treatment, Severe Pain Treatment
By Companies
Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
160
Number of Tables & Figures
112
Customization Available
Yes, the report can be customized as per your need.
Global Opioid Use Disorder Market Report Segments:
The global Opioid Use Disorder market is segmented on the basis of:
Types
Buprenorphine, Methadone, Naltrexone
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Moderate Pain Treatment, Severe Pain Treatment
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Indivior
- Alkermes
- Titan Pharmaceuticals
- Hikma Pharmaceuticals
- Teva Pharmaceuticals
- MediciNova
- Orexo
- Camurus
- Omeros
Highlights of The Opioid Use Disorder Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Buprenorphine
- Methadone
- Naltrexone
- By Application:
- Moderate Pain Treatment
- Severe Pain Treatment
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Opioid Use Disorder Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Opioid use disorder is a mental health condition that is characterized by continued opioid use despite harmful consequences. The most common harms associated with opioid use disorder include addiction, overdose, and death.
Some of the major companies in the opioid use disorder market are Indivior, Alkermes, Titan Pharmaceuticals, Hikma Pharmaceuticals, Teva Pharmaceuticals, MediciNova, Orexo, Camurus, Omeros.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Opioid Use Disorder Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Opioid Use Disorder Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Opioid Use Disorder Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Opioid Use Disorder Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Opioid Use Disorder Market Size & Forecast, 2018-2028
4.5.1 Opioid Use Disorder Market Size and Y-o-Y Growth
4.5.2 Opioid Use Disorder Market Absolute $ Opportunity
Chapter 5 Global Opioid Use Disorder Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Opioid Use Disorder Market Size Forecast by Type
5.2.1 Buprenorphine
5.2.2 Methadone
5.2.3 Naltrexone
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Opioid Use Disorder Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Opioid Use Disorder Market Size Forecast by Applications
6.2.1 Moderate Pain Treatment
6.2.2 Severe Pain Treatment
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Opioid Use Disorder Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Opioid Use Disorder Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Opioid Use Disorder Analysis and Forecast
9.1 Introduction
9.2 North America Opioid Use Disorder Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Opioid Use Disorder Market Size Forecast by Type
9.6.1 Buprenorphine
9.6.2 Methadone
9.6.3 Naltrexone
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Opioid Use Disorder Market Size Forecast by Applications
9.10.1 Moderate Pain Treatment
9.10.2 Severe Pain Treatment
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Opioid Use Disorder Analysis and Forecast
10.1 Introduction
10.2 Europe Opioid Use Disorder Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Opioid Use Disorder Market Size Forecast by Type
10.6.1 Buprenorphine
10.6.2 Methadone
10.6.3 Naltrexone
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Opioid Use Disorder Market Size Forecast by Applications
10.10.1 Moderate Pain Treatment
10.10.2 Severe Pain Treatment
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Opioid Use Disorder Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Opioid Use Disorder Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Opioid Use Disorder Market Size Forecast by Type
11.6.1 Buprenorphine
11.6.2 Methadone
11.6.3 Naltrexone
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Opioid Use Disorder Market Size Forecast by Applications
11.10.1 Moderate Pain Treatment
11.10.2 Severe Pain Treatment
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Opioid Use Disorder Analysis and Forecast
12.1 Introduction
12.2 Latin America Opioid Use Disorder Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Opioid Use Disorder Market Size Forecast by Type
12.6.1 Buprenorphine
12.6.2 Methadone
12.6.3 Naltrexone
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Opioid Use Disorder Market Size Forecast by Applications
12.10.1 Moderate Pain Treatment
12.10.2 Severe Pain Treatment
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Opioid Use Disorder Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Opioid Use Disorder Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Opioid Use Disorder Market Size Forecast by Type
13.6.1 Buprenorphine
13.6.2 Methadone
13.6.3 Naltrexone
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Opioid Use Disorder Market Size Forecast by Applications
13.10.1 Moderate Pain Treatment
13.10.2 Severe Pain Treatment
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Opioid Use Disorder Market: Competitive Dashboard
14.2 Global Opioid Use Disorder Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Indivior
14.3.2 Alkermes
14.3.3 Titan Pharmaceuticals
14.3.4 Hikma Pharmaceuticals
14.3.5 Teva Pharmaceuticals
14.3.6 MediciNova
14.3.7 Orexo
14.3.8 Camurus
14.3.9 Omeros
